NCT00343317View on ClinicalTrials.gov

Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women

NACompletedINTERVENTIONAL

Enrollment

1,372

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

May 31, 2005

Conditions

Puerperal Sepsis

Interventions

DRUG

Intrapartum Cefoxitin (2g) vs. placebo

Trial Locations (1)

4013

University of KwaZulu-Natal / King Edward VIII Hospital, Durban

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of KwaZulu

OTHER

NCT00343317 - Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women | Biotech Hunter | Biotech Hunter